INSIGHTS ON CELL & GENE THERAPY DISCOVERY

• A Guide To Plasmid Selection In Drug Discovery: Starting With The End In Mind

  Clinical development milestones are built on the foundations and achievements of previous phases. Explore the importance of an effective strategy, working backwards from the end-goal: commercialization.

• Streamlining And Standardizing Cell And Gene Therapies From Process To Product

  Cell and gene therapies are transforming the lives of patients with various rare genetic diseases and more common conditions such as cancer. However, the rapid pace of scientific progress has overwhelmed supply infrastructure, creating pressures to scale manufacturing, increase capacity and meet a wide range of deliverable requirements.

• Mind The Cell And Gene Gap

  Without further training and a boost in headcount, there is the possibility of a bottleneck in the rollout of advanced medicines that could ultimately cost the lives of patients. Find out more in this article.

• The Story Behind The Media

  Learn more about a system that fuels the rapid commercialization of scalable regenerative cures.

• Autologous And Allogeneic Cell Therapies: Benefits, Challenges, And Future Prospects

  In this blog, explore both autologous and allogeneic approaches, the solutions needed to optimize the development processes for commercial viability, and the future landscape of cell therapies in the rare disease space.

• 5 Translational Research Challenges On The Path To Patients

  As a translational researcher, you’re paving an uncharted path toward exciting new possibilities in healthcare. Explore five difficulties translational researchers face when developing a new therapy.

• Viral Vectors For Gene Therapy: What To Expect In 2023

  Explore viral vectors, an indispensable means to modify the genetic material of human cells, and their future in gene therapy.

• Long-Term Follow-Up Studies: Gene Therapy Products, Protocols And Potential Issues

  A “long-term” study is one that gathers data on research subjects for 5 years or more. Learn about several arguments for conducting studies to assessing the long-term risk of drugs in this blog.

• Stable Cell Lines For Lentivirus And Gammaretrovirus Production

  Explore the advantages and disadvantages of transient transfection and the reasons many viral vector (VV) developers are moving towards using stable producer cell lines for lentiviral vector (LV) development.

• What’s Next For Advanced Therapies?

  The advanced therapies sector is growing exponentially. This paper discusses the future of advanced therapies from the perspective of industry leaders.